CureVac's CVGBM Cancer Vaccine Induces Promising Immune Responses in Phase 1 Study in Glioblastoma Presented at the ESMO 2024 Congress
Preliminary immunogenicity results demonstrate induction of cancer antigen-specific T-cell responses in 77% of evaluable patients following CVGBM monotherapy 84% of immune responses were de novo, observed in patients without pre-existing T-cell activity against encoded cancer antigens CVGBM was generally well tolerated up to the highest tested dose level of 100 µg with no dose-limiting toxicities Most common adverse events were mild to moderate systemic reactions such as headache, fever and chills, which resolved within 1-2 days post injection 100 µg was selected as the recommended dose for the dose expansion phase, which recently started enrollment TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 13, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today presented compelling data from the dose-escalation Part A of its ongoing Phase 1 CVGBM cancer vaccine study in patients with glioblastoma at the European Society for Medical Oncology (ESMO) Congress.
CureVac to Present First CVGBM Glioblastoma Cancer Vaccine Clinical Data at ESMO 2024 Congress
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / September 9, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced that the first clinical data from CureVac's ongoing Phase 1 CVGBM cancer vaccine study in patients with resected glioblastoma will be presented at the European Society for Medical Oncology (ESMO) Congress (Barcelona, Spain, September 13-17, 2024).
CureVac Advances Cancer Vaccine Candidate CVGBM to Part B of Phase 1 Study in Patients with Resected Glioblastoma
First patient administered in dose-confirmation Part B of Phase 1 study with mRNA-based, multiepitope cancer vaccine candidate CVGBM Part B expected to include up to 20 patients to generate extended data on safety, tolerability, and immunogenicity of CVGBM TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced the start of the dose-confirmation Part B of its ongoing Phase 1 study in patients with resected glioblastoma.
CureVac Names Oncologist and Drug Development Expert Dr. Mehdi Shahidi to Supervisory Board
TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / August 15, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today named clinical oncologist Mehdi Shahidi, M.D.
CureVac N.V. (CVAC) Expected to Beat Earnings Estimates: Should You Buy?
CureVac (CVAC) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
CureVac (CVAC) Upgraded to Buy: What Does It Mean for the Stock?
CureVac (CVAC) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
CureVac Layoffs 2024: What to Know About the Latest CVAC Job Cuts
CureVac (NASDAQ: CVAC ) layoffs are coming for the vaccine maker's employees as it prepares to undergo a restructuring to streamline its business. CureVac has announced that its layoffs will affect 30% of its global workforce.
CVAC Stock Alert: CureVac Pops on Licensing Deal With GSK
CureVac (NASDAQ: CVAC ) stock is on the rise Wednesday after the company announced a restructured licensing agreement with GSK (NYSE: GSK ). This new agreement has GSK taking over the development and manufacturing of certain vaccines made by CureVac.
CureVac Initiates Strategic Restructuring to Align Resources with Focus on High-Value mRNA Pipeline Opportunities
Strategic restructuring includes a workforce reduction of approximately 30%, re-focusing on research, development, and innovation to create leaner and more agile organization Prioritization of high-value opportunities in oncology and other selected diseases, leveraging proprietary mRNA technology to develop novel treatment approaches Company expects to deliver two or more clinical candidates by the end of 2025 and plans to initiate at least two new Phase 1 studies by the end of 2026 Cash runway extended into 2028 through combination of new licensing agreement with GSK, reduced operating expenses and enhanced financial discipline TÜBINGEN, GERMANY and BOSTON, MA / ACCESSWIRE / July 3, 2024 / CureVac N.V. (Nasdaq:CVAC) ("CureVac"), a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid ("mRNA"), today announced a significant strategic restructuring to focus its resources on high-value mRNA projects in oncology and other select areas of substantial unmet medical need.
